Related Experiment Video
Updated: Apr 17, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.9K
Stereotactic body radiotherapy for prostate cancer
D R Henderson1, A C Tree1, N J van As1
1Academic Uro-oncology Department, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|February 25, 2015
Summary
Stereotactic body radiotherapy (SBRT) for prostate cancer shows promising medium-term results comparable to standard radiotherapy. This hypofractionated approach may improve outcomes and patient quality of life, with potential for treating oligometastatic disease.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Stereotactic body radiotherapy (SBRT) is increasingly used for localized prostate cancer.
- Non-randomized data suggest medium-term outcomes are consistent with standard radiotherapy.
- Prostate cancer's low alpha/beta ratio may favor hypofractionation, allowing for dose escalation.
Purpose of the Study:
- To evaluate the efficacy and potential benefits of SBRT for localized prostate cancer.
- To explore the role of SBRT in treating oligometastatic prostate cancer.
- To assess SBRT's potential for cost reduction and improved patient quality of life.
Main Methods:
- Review of non-randomized data for localized prostate cancer treated with SBRT.
- Analysis of SBRT's application in oligometastatic prostate cancer.
- Consideration of treatment delivery in five attendances.
Main Results:
- Medium-term outcomes for localized prostate cancer treated with SBRT are comparable to standard radiotherapy.
- SBRT offers potential for isotoxic dose escalation due to a favorable therapeutic ratio.
- Early outcomes in oligometastatic prostate cancer suggest delayed disease progression and deferred androgen deprivation therapy.
Conclusions:
- SBRT is a viable treatment option for localized prostate cancer, with outcomes similar to conventional radiotherapy.
- Randomized trials are necessary to definitively establish SBRT's relative benefits.
- SBRT shows promise in managing oligometastatic prostate cancer, potentially delaying progression and the need for ADT.
